ClinVar Miner

Submissions for variant NM_000551.4(VHL):c.264G>A (p.Trp88Ter)

dbSNP: rs869025622
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001205532 SCV001376794 pathogenic Chuvash polycythemia; Von Hippel-Lindau syndrome 2019-05-23 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Trp88*) in the VHL gene. It is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in VHL are known to be pathogenic (PMID: 8956040, 12202531). This variant has been observed in individuals affected with von Hippel-Lindau syndrome (PMID: 25069792, 28469506).
Ambry Genetics RCV003163557 SCV003858789 pathogenic Hereditary cancer-predisposing syndrome 2023-01-26 criteria provided, single submitter clinical testing The p.W88* pathogenic mutation (also known as c.264G>A), located in coding exon 1 of the VHL gene, results from a G to A substitution at nucleotide position 264. This changes the amino acid from a tryptophan to a stop codon within coding exon 1. This alteration has been observed in multiple individuals with a personal and/or family history that is consistent with VHL-related disease (Ambry internal data; Zhang M et al. Endocrine, 2015 Feb;48:83-; Mathó C et al. Genet Test Mol Biomarkers, 2016 Dec;20:771-776; Sriphrapradang C et al. Clin Med Insights Endocrinol Diabetes, 2017 Apr;10:1179551417705122; Lee SH et al. Korean J Ophthalmol, 2022 Dec;36:543-549). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.